ETF Managers Group’s GW Pharmaceuticals Plc American Depositary Shares GWPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-862,727
Closed -$187M 825
2021
Q1
$187M Buy
862,727
+241,366
+39% +$45.4M 3.32% 1
2020
Q4
$71.7M Buy
621,361
+246,017
+66% +$27.6M 1.57% 6
2020
Q3
$36.5M Sell
375,344
-104,801
-22% -$12.1M 1.16% 34
2020
Q2
$58.9M Buy
480,145
+17,898
+4% +$2.03M 2.09% 2
2020
Q1
$40.5M Sell
462,247
-10,131
-2% -$1.07M 1.88% 6
2019
Q4
$49.4M Sell
472,378
-50,041
-10% -$5.61M 1.72% 6
2019
Q3
$60.1M Sell
522,419
-53,868
-9% -$8.18M 2.16% 3
2019
Q2
$99.3M Buy
+576,287
New +$99.7M 3.16% 1
2019
Q1
Sell
-190,396
Closed -$18.1M 589
2018
Q4
$18.1M Buy
+190,396
New +$25M 0.85% 29
2018
Q2
Sell
-172,891
Closed -$18.3M 617
2018
Q1
$18.3M Buy
172,891
+148,779
+617% +$18.7M 1.11% 18
2017
Q4
$3.23M Buy
+24,112
New +$2.83M 0.23% 61

Other funds holding GWPH

ETF Managers Group's GWPH Position: Q2 2021 in Review

ETF Managers Group sold out of GW Pharmaceuticals Plc American Depositary Shares (GWPH) in Q2 2021, closing a stake of 862,727 shares — an estimated $187M sold.

ETF Managers Group first reported a position in GWPH in Q4 2017 and held it in 11 quarters. The position peaked at $187M in Q1 2021. 1 fund tracked by Wall St. Rank holds GWPH as of Q2 2021.

  • ETF Managers Group reported no remaining GW Pharmaceuticals Plc American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • ETF Managers Group sold 862,727 GW Pharmaceuticals Plc American Depositary Shares shares in Q2 2021, an estimated $187M.
  • ETF Managers Group first reported a position in GW Pharmaceuticals Plc American Depositary Shares in Q4 2017 and held it in 11 quarters.
  • ETF Managers Group's GW Pharmaceuticals Plc American Depositary Shares position peaked at $187M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held GW Pharmaceuticals Plc American Depositary Shares as of Q2 2021.

Based on ETF Managers Group's 13F filing for Q2 2021, filed 16 Aug 2021.